Search

Your search keyword '"Suzanne E. Schindler"' showing total 46 results
Start Over Author "Suzanne E. Schindler" Topic developmental neuroscience
46 results on '"Suzanne E. Schindler"'

1. Adverse driving behaviors increase over time as a function of preclinical Alzheimer's disease biomarkers

Author

Jason M, Doherty, Samantha A, Murphy, Sayeh, Bayat, Julie K, Wisch, Ann M, Johnson, Alexis, Walker, Suzanne E, Schindler, Beau M, Ances, John C, Morris, and Ganesh M, Babulal

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Abstract

We investigated the relationship between preclinical Alzheimer's disease (AD) biomarkers and adverse driving behaviors in a longitudinal analysis of naturalistic driving data.Naturalistic driving data collected using in-vehicle dataloggers from 137 community-dwelling older adults (65+) were used to model driving behavior over time. Cerebrospinal fluid (CSF) biomarkers were used to identify individuals with preclinical AD. Additionally, hippocampal volume and cognitive biomarkers for AD were investigated in exploratory analyses.CSF biomarkers predicted the longitudinal trajectory of the incidence of adverse driving behavior. Abnormal amyloid beta (AβPreclinical AD is associated with increased adverse driving behavior over time that cannot be explained by cognitive changes. Driving behavior as a functional, neurobehavioral marker may serve as an early detection for decline in preclinical AD. Screening may also help prolong safe driving as older drivers age.

Published
2022
Full Text
View/download PDF

2. A flexible modeling approach for biomarker‐based computation of absolute risk of Alzheimer's disease dementia

Author

Sarah M. Hartz, Jessica Mozersky, Suzanne E. Schindler, Erin Linnenbringer, Junwei Wang, Brian A. Gordon, Cyrus A. Raji, Krista L. Moulder, Tim West, Tammie L. S. Benzinger, Carlos Cruchaga, Jason J. Hassenstab, Laura J. Bierut, Chengjie Xiong, and John C. Morris

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Abstract

As Alzheimer's disease (AD) biomarkers rapidly develop, tools are needed that accurately and effectively communicate risk of AD dementia.We analyzed longitudinal data from10,000 cognitively unimpaired older adults. Five-year risk of AD dementia was modeled using survival analysis.A demographic model was developed and validated on independent data with area under the receiver operating characteristic curve (AUC) for 5-year prediction of AD dementia of 0.79. Clinical and cognitive variables (AUC = 0.79), and apolipoprotein E genotype (AUC = 0.76) were added to the demographic model. We then incorporated the risk computed from the demographic model with hazard ratios computed from independent data for amyloid positron emission tomography status and magnetic resonance imaging hippocampal volume (AUC = 0.84), and for plasma amyloid beta (Aβ)42/Aβ40 (AUC = 0.82).An adaptive tool was developed and validated to compute absolute risks of AD dementia. This approach allows for improved accuracy and communication of AD risk among cognitively unimpaired older adults.

Published
2022
Full Text
View/download PDF

4. Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults

Author

Chengjie Xiong, Jingqin Luo, Suzanne E. Schindler, Anne M. Fagan, Tammie Benzinger, Jason Hassenstab, Joyce E. Balls‐Berry, Folasade Agboola, Elizabeth Grant, Krista L. Moulder, and John C. Morris

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Abstract

Longitudinal changes in Alzheimer's disease (AD) biomarkers, including cerebrospinal fluid (CSF) analytes, amyloid uptakes from positron emission tomography (PET), structural outcomes from magnetic resonance imaging (MRI), and cognition, have not been compared between Blacks and Whites.A total of 179 Blacks and 1180 Whites who were cognitively normal at baseline and had longitudinal data from at least one biomarker modality were analyzed for the annual rates of change.CSF amyloid beta (Aβ)42/Aβ40 declined more slowly (P = .0390), and amyloid (PET) accumulated more slowly (P = .0157), in Blacks than Whites. CSF Aβ42 changed in opposite directions over time between Blacks and Whites (P = .0039). The annual increase in CSF total tau and phosphorylated tau181 for Blacks was about half of that for Whites.Longitudinal racial differences in amyloid biomarkers are observed. It will be important to comprehensively and prospectively examine the effects of apolipoprotein E genotype and sociocultural factors on these differences.

Published
2022
Full Text
View/download PDF

5. SORTOUT‐AB: A Study of Race to Understand Alzheimer Biomarkers

Author

Chengjie Xiong, David A. Wolk, James J. Lah, Carey E. Gleason, Erik D Roberson, Tammie L.S. Benzinger, Suzanne E. Schindler, Anne M. Fagan, Jason J. Hassenstab, Krista L. Moulder, Joyce E Balls‐Berry, Reisa A. Sperling, Keith A. Johnson, Allan I. Levey, Sterling C. Johnson, Jingqin Luo, Emily Gremminger, Folasade Agboola, Elizabeth A Grant, Beau M Ances, Brian A. Gordon, Russ C. Hornbeck, Parinaz Massoumzadeh, Sarah J. Keefe, Donna Dierker, Julia D Gray, Jessica Andrews, Rachel L. Henson, Marissa Streitz, Cecelia Manzanares, Deqiang Qiu, Dawn Mechanic‐Hamilton, Shana D. Stites, Leslie M. Shaw, Sharnita Midgett, and John C. Morris

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

8. Comparing neuroimaging and cerebrospinal fluid markers of amyloid, tau, and neurodegenerative biomarkers: implications for understanding the biology of the disease

Author

Brian A. Gordon, Julie K. Wisch, Diana A. Hobbs, Nicole S. McKay, Stephanie A. Schultz, Shaney Flores, Aylin Dincer, Sarah J. Keefe, Beau M Ances, John C. Morris, Suzanne E. Schindler, Anne M. Fagan, and Tammie L.S. Benzinger

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

9. A methodology for normalizing fluid biomarker concentrations across reagent lots

Author

Rachel L. Henson, Katherine Volluz, Benjamin A. Saef, Courtney L. Sutphen, Elizabeth M. Herries, John C. Morris, Anne M. Fagan, Chengjie Xiong, and Suzanne E. Schindler

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

10. Pooling CSF Measurements Across Multiple Cohorts in the Preclinical Alzheimer's Consortium

Author

Vishnu Suresh Lokhande, Jiangxia Wang, Anja Soldan, Corinne Pettigrew, Abhay Moghekar, John C. Morris, Anne M. Fagan, Suzanne E. Schindler, Chengjie Xiong, Marilyn S. Albert, Sterling C. Johnson, and Vikas Singh

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

11. Baseline White Matter Neuroinflammation Predicts Cognitive Decline in Alzheimer Disease

Author

Qing Wang, Wenshang Wang, Suzanne E. Schindler, Nicole S. McKay, Gengsheng Chen, Jingxia Liu, Sicheng Wang, Zhexian Sun, Jason J. Hassenstab, Anne M. Fagan, John C. Morris, Yong Wang, and Tammie L.S. Benzinger

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

12. The relationship of soluble p‐tau isoforms with brain amyloid and tau deposition in sporadic AD

Author

Nicolas R. Barthélemy, Benjamin A. Saef, Yan Li, Brian A. Gordon, Yingxin He, Kanta Horie, Chihiro Sato, Vitaliy Ovod, Tammie L.S. Benzinger, John C. Morris, Randall J. Bateman, and Suzanne E. Schindler

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

13. Modeling functional and structural brain‐predicted age in relation to Alzheimer disease and cognition

Author

Peter R Millar, Patrick H Luckett, Brian A. Gordon, Tammie L.S. Benzinger, Anne M. Fagan, Jason J. Hassenstab, Suzanne E. Schindler, John C. Morris, and Beau M Ances

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

14. Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau

Author

Anne M. Fagan, Suzanne E. Schindler, Carlos Cruchaga, Julie K. Wisch, David M. Holtzman, John C. Morris, Karin L. Meeker, Beau M. Ances, Tammie L.S. Benzinger, and Omar Butt

Subjects
Male, 0301 basic medicine, Apolipoprotein E, Amyloid, Heterozygote, medicine.medical_specialty, Epidemiology, Amyloid beta, Apolipoprotein E4, Prodromal Symptoms, tau Proteins, Article, 03 medical and health sciences, Cellular and Molecular Neuroscience, Cognition, 0302 clinical medicine, Cerebrospinal fluid, Developmental Neuroscience, Alzheimer Disease, Internal medicine, mental disorders, medicine, Humans, Allele, Pathological, Aged, Subclinical infection, biology, Resting state fMRI, business.industry, Health Policy, Brain, Default Mode Network, Magnetic Resonance Imaging, Psychiatry and Mental health, 030104 developmental biology, Endocrinology, Positron-Emission Tomography, biology.protein, Female, Neurology (clinical), Geriatrics and Gerontology, business, Biomarkers, 030217 neurology & neurosurgery
Abstract

INTRODUCTION: Apolipoprotein E (APOE) ε4 allele status is associated with amyloid and tau-related pathological changes related to Alzheimer’s disease (AD). However, it is unknown whether brain network changes are related to Aβ and/or tau-related pathology in cognitively normal APOE ε4 carriers with sub-threshold amyloid (Aβ) accumulation. METHODS: Resting state functional connectivity (rs-fc) measures of network integrity were evaluated in cognitively normal individuals (n=121, mean age 76.6 ± 7.8 years, 15% APOE ε4 carriers, 65% female) with minimal Aβ per cerebrospinal fluid (CSF) or amyloid positron emission tomography (PET). RESULTS: APOE ε4 carriers had increased lateralized connections relative to callosal connections within the default-mode, memory, and salience networks (p = 0.02), with significant weighting on linear regression towards CSF total tau (p = 0.03) and CSF phosphorylated tau at codon 181 (p = 0.03), but not CSF Aβ(42). DISCUSSION: Cognitively normal APOE ε4 carriers with sub-threshold amyloid accumulation may have network reorganization associated with tau.

Published
2021
Full Text
View/download PDF

15. CSF and blood plasma mass spectrometry measures of Aβ, tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimer’s disease

Author

Randall J. Bateman, Nicolas R. Barthelemy, Tammie L.S. Benzinger, James G. Bollinger, Anne M. Fagan, Brian A. Gordon, Oskar Hansson, David M. Holtzman, Kanta Horie, Melody Li, Colin L Masters, Kwasi G. Mawuenyega, Eric McDade, John C. Morris, Vitaliy Ovod, Melissa Budelier, Chloe He, Ronald C. Petersen, Michelle M. Mielke, Chihiro Sato, Suzanne E. Schindler, Leslie M. Shaw, John Q Trojanowski, Mike W. Weiner, and Chengjie Xiong

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2021
Full Text
View/download PDF

16. Correspondence of CSF biomarkers measured by Lumipulse assays with amyloid PET

Author

Katherine E. Volluz, Suzanne E. Schindler, Rachel L. Henson, Chengjie Xiong, Brian A. Gordon, Tammie L.S. Benzinger, David M. Holtzman, John C. Morris, and Anne M. Fagan

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2021
Full Text
View/download PDF

17. Clinical, cognitive and biomarker profiles in dominantly‐inherited versus sporadic early‐onset Alzheimer’s disease

Author

Jorge J Llibre‐Guerra, Leonardo Iaccarino, Yan Li, Lauren Edwards, Eric McDade, Amelia Strom, Brian A. Gordon, Nidhi Mundada, Suzanne E. Schindler, Elena Tsoy, Anne M Fagan, Renaud La Joie, Tammie L.S. Benzinger, David N. Soleimani‐Meigooni, Andrew J. Aschenbrenner, Zachary A. Miller, Guoqiao Wang, Joel H Kramer, Jason Hassenstab, Howard J. Rosen, John C. Morris, Bruce L. Miller, Chengjie Xiong, Richard J. Perrin, Gil D. Rabinovici, and Randall J. Bateman

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2021
Full Text
View/download PDF

19. Presence of co‐pathology in sporadic early‐onset Alzheimer disease versus dominantly inherited Alzheimer disease

Author

Jorge J Llibre‐Guerra, Yan Li, Erin E. Franklin, Carol A Miller, Andrew F Teich, Julia Kofler, Dennis W Dickson, Bernardino Francesco Ghetti, Matthew P. Frosch, Glenda M Halliday, Catriona McLean, Tammaryn Lashley, Brian A. Gordon, Suzanne E. Schindler, Charles D. Chen, Anne M. Fagan, Tammie L.S. Benzinger, Guoqiao Wang, Jason Hassenstab, John C. Morris, Randall J. Bateman, Richard J. Perrin, and Eric McDade

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2021
Full Text
View/download PDF

20. Imaging measures of molecular pathology and neurodegeneration in dominantly‐inherited and sporadic early‐onset Alzheimer’s Disease

Author

Leonardo Iaccarino, Jorge J. Llibre‐Guerra, Lauren Edwards, Nidhi Mundada, Amelia Strom, Elena Tsoy, Yan Li, Brian A. Gordon, Suzanne E. Schindler, Anne M. Fagan, Tammie L.S. Benzinger, Guoqiao Wang, Jason Hassenstab, John C. Morris, Chengjie Xiong, Richard J. Perrin, David N. Soleimani‐Meigooni, Zachary A. Miller, Joel H. Kramer, Howard J. Rosen, Renaud La Joie, Bruce L. Miller, Randall J. Bateman, and Gil D. Rabinovici

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2021
Full Text
View/download PDF

21. White matter neuroinflammation correlates cognition in preclinical Alzheimer disease

Author

Qing Wang, Suzanne E. Schindler, Gengsheng Chen, Nicole S. McKay, Jingxia Liu, Shaney E. Flores, Sicheng Wang, Jason Hassenstab, John C. Morris, Yong Wang, and Tammie L.S. Benzinger

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2021
Full Text
View/download PDF

23. Neurofilament light is a non‐specific marker of aging and white matter integrity

Author

Karin L. Meeker, Courtney L. Sutphen, Anne M. Fagan, Tammie L.S. Benzinger, Suzanne E. Schindler, John C. Morris, Brian A. Gordon, and Beau M. Ances

Subjects
Epidemiology, Chemistry, Health Policy, Neurofilament light, Cell biology, White matter, Psychiatry and Mental health, Cellular and Molecular Neuroscience, medicine.anatomical_structure, Developmental Neuroscience, Non specific, medicine, Neurology (clinical), Geriatrics and Gerontology
Published
2020
Full Text
View/download PDF

24. Association between cerebrospinal fluid neurofilament light chain and markers of neurofibrillary pathophysiology: Findings from the Knight Alzheimer Disease Research Center

Author

Anne M. Fagan, Suzanne E. Schindler, John C. Morris, Brian A. Gordon, Stephanie A. Schultz, Courtney L. Sutphen, Charles D. Chen, and Tammie L.S. Benzinger

Subjects
Epidemiology, business.industry, Health Policy, Neurofilament light, medicine.disease, Pathophysiology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Cerebrospinal fluid, Developmental Neuroscience, Neuroimaging, Biomarker (medicine), Medicine, Neurology (clinical), Geriatrics and Gerontology, Alzheimer's disease, business, Neuroscience
Published
2020
Full Text
View/download PDF

25. Mass spectrometry measures of plasma Aβ, tau and P‐tau isoforms’ relationship to amyloid PET, tau PET, and clinical stage of Alzheimer’s disease

Author

David M. Holtzman, Anne M. Fagan, Chihiro Sato, Kwasi G. Mawuenyega, Kanta Horie, Melody Li, Michael W. Weiner, Tammie L.S. Benzinger, Colin L. Masters, Suzanne E. Schindler, Eric McDade, Yan Li, Nicolas R. Barthélemy, John C. Morris, James G. Bollinger, Randall J. Bateman, Chengjie Xiong, Vitaliy Ovod, Brian A. Gordon, and Oskar Hansson

Subjects
Gene isoform, Pathology, medicine.medical_specialty, Epidemiology, Chemistry, Health Policy, Amyloid pet, Mass spectrometry, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Neurology (clinical), Geriatrics and Gerontology, Stage (cooking)
Published
2020
Full Text
View/download PDF

26. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

Author

April Ross, Kaj Blennow, Leslie M. Shaw, Doug R. Galasko, Suzanne E. Schindler, James Hendrix, Courtney Ramus, Jalayne J. Arias, Sheila Fifer, José Luis Molinuevo, Maria C. Carrillo, Judit Illes, and Stephen Salloway

Subjects
0301 basic medicine, medicine.medical_specialty, Delphi Technique, Epidemiology, Psychological intervention, Disease, Spinal Puncture, Appropriate Use Criteria, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Cerebrospinal fluid, Developmental Neuroscience, Alzheimer Disease, medicine, Humans, Workgroup, Intensive care medicine, medicine.diagnostic_test, Lumbar puncture, business.industry, Health Policy, Psychiatry and Mental health, 030104 developmental biology, Practice Guidelines as Topic, Csf analysis, Research questions, Neurology (clinical), Geriatrics and Gerontology, business, Biomarkers, 030217 neurology & neurosurgery
Abstract

Introduction The Alzheimer's Association convened a multidisciplinary workgroup to develop appropriate use criteria to guide the safe and optimal use of the lumbar puncture procedure and cerebrospinal fluid (CSF) testing for Alzheimer's disease pathology detection in the diagnostic process. Methods The workgroup, experienced in the ethical use of lumbar puncture and CSF analysis, developed key research questions to guide the systematic review of the evidence and developed clinical indications commonly encountered in clinical practice based on key patient groups in whom the use of lumbar puncture and CSF may be considered as part of the diagnostic process. Based on their expertise and interpretation of the evidence from systematic review, members rated each indication as appropriate or inappropriate. Results The workgroup finalized 14 indications, rating 6 appropriate and 8 inappropriate. Discussion In anticipation of the emergence of more reliable CSF analysis platforms, the manuscript offers important guidance to health-care practitioners and suggestions for implementation and future research.

Published
2018
Full Text
View/download PDF

27. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

Author

Marian Quan, Richard Batrla-Utermann, John C. Morris, Anne M. Fagan, Chengjie Xiong, Suzanne E. Schindler, Tammie L.S. Benzinger, Brian A. Gordon, Simone Wahl, David M. Holtzman, and Julia D. Gray

Subjects
Male, 0301 basic medicine, Amyloid, Pathology, medicine.medical_specialty, Epidemiology, tau Proteins, Article, Cohort Studies, 03 medical and health sciences, Cellular and Molecular Neuroscience, chemistry.chemical_compound, 0302 clinical medicine, Cerebrospinal fluid, Developmental Neuroscience, Alzheimer Disease, mental disorders, Humans, Medicine, Aged, Immunoassay, Amyloid beta-Peptides, Aniline Compounds, medicine.diagnostic_test, business.industry, Health Policy, Brain, Middle Aged, Peptide Fragments, Amyloid β peptide, Thiazoles, Psychiatry and Mental health, 030104 developmental biology, chemistry, Positron emission tomography, Positron-Emission Tomography, Csf biomarkers, Biomarker (medicine), Female, Neurology (clinical), Radiopharmaceuticals, Geriatrics and Gerontology, business, Pittsburgh compound B, Automated immunoassay, Biomarkers, 030217 neurology & neurosurgery
Abstract

Introduction Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181 are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, but variability in manual plate-based assays has limited their use. We examined the relationship between CSF biomarkers, as measured by a novel automated immunoassay platform, and amyloid positron emission tomography. Methods CSF samples from 200 individuals underwent separate analysis for Aβ42, total tau, and phosphorylated tau-181 with automated Roche Elecsys assays. Aβ40 was measured with a commercial plate-based assay. Positron emission tomography with Pittsburgh Compound B was performed less than 1 year from CSF collection. Results Ratios of CSF biomarkers (total tau/Aβ42, phosphorylated tau-181/Aβ42, and Aβ42/Aβ40) best discriminated Pittsburgh Compound B–positive from Pittsburgh Compound B–negative individuals. Discussion CSF biomarkers and amyloid positron emission tomography reflect different aspects of Alzheimer's disease brain pathology, and therefore, less-than-perfect correspondence is expected. Automated assays are likely to increase the utility of CSF biomarkers.

Published
2018
Full Text
View/download PDF

28. Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years

Author

Anne M. Fagan, Suzanne E. Schindler, Charlotte E. Teunissen, Lena McCue, Chengjie Xiong, John C. Morris, Courtney L. Sutphen, Philip Scheltens, David M. Holtzman, Sandra D. Mulder, Amsterdam Neuroscience - Neurodegeneration, Clinical chemistry, and Neurology

Subjects
Male, 0301 basic medicine, Aging, Pathology, medicine.medical_specialty, Future studies, Amyloid β, Epidemiology, Urology, tau Proteins, Total tau, Diagnostic accuracy, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Cerebrospinal fluid, Developmental Neuroscience, Alzheimer Disease, medicine, Humans, Longitudinal Studies, Aged, Amyloid beta-Peptides, Aniline Compounds, medicine.diagnostic_test, business.industry, Health Policy, Brain, Middle Aged, medicine.disease, Peptide Fragments, Thiazoles, Psychiatry and Mental health, 030104 developmental biology, ROC Curve, Positron-Emission Tomography, Tau phosphorylation, Immunoassay, Female, Neurology (clinical), Geriatrics and Gerontology, Alzheimer's disease, business, 030217 neurology & neurosurgery
Abstract

Introduction The best-established cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease are levels of amyloid β 42 (Aβ42), total tau (tau), and phosphorylated tau 181 (ptau). We examined whether a widely used commercial immunoassay for CSF Aβ42, tau, and ptau provided stable measurements for more than ∼10 years. Methods INNOTEST assay values for CSF Aβ42, tau, and ptau from Washington University in St. Louis and VU Medical Center, Amsterdam, were evaluated. Results Aβ42 values as measured by the INNOTEST assay drifted upward by approximately 3% per year over the past decade. Tau values remained relatively stable, whereas results for ptau were mixed. Discussion Assay drift may reduce statistical power or even confound analyses. The drift in INNOTEST Aβ42 values may reduce diagnostic accuracy for Alzheimer's disease in the clinic. We recommend methods to account for assay drift in existing data sets and to reduce assay drift in future studies.

Published
2018
Full Text
View/download PDF

29. Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease

Author

Elizabeth A. Grant, Frans R.J. Verhey, Chengjie Xiong, Suzanne E. Schindler, Anne M. Fagan, Jason Hassenstab, Isabelle Bos, John C. Morris, Stephanie J.B. Vos, Pieter Jelle Visser, Neurology, Amsterdam Neuroscience - Neurodegeneration, Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, and MUMC+: MA Med Staf Spec Psychiatrie (9)

Subjects
Male, 0301 basic medicine, Oncology, Epidemiology, Framingham Risk Score, BLOOD-PRESSURE, Disease, Cognition, 0302 clinical medicine, Cerebrospinal fluid, Risk Factors, biology, Depression, Health Policy, DEMENTIA, NEURODEGENERATION, Alzheimer's disease, Cardiovascular disorders, Psychiatry and Mental health, Vascular risk factors, Cardiovascular Diseases, Hypertension, Biomarker (medicine), Female, Amyloid-beta, medicine.medical_specialty, Amyloid, Amyloid beta, Hypercholesterolemia, BIOMARKERS, Prodromal Symptoms, tau Proteins, Neuropathology, Article, 03 medical and health sciences, Cellular and Molecular Neuroscience, Developmental Neuroscience, Alzheimer Disease, Internal medicine, medicine, Humans, Dementia, Obesity, LOAD, Aged, Amyloid beta-Peptides, business.industry, CARE, medicine.disease, PATHOLOGY, 030104 developmental biology, biology.protein, Neurology (clinical), Geriatrics and Gerontology, Tau, business, NEUROPATHOLOGY, 030217 neurology & neurosurgery
Abstract

Introduction: Vascular factors increase the risk of Alzheimer's disease (AD). We investigated the associations between such factors, longitudinal AD cerebrospinal fluid biomarkers, and cognition.Methods: 433 cognitively normal participants were classified into four biomarker groups using their baseline amyloid (A+/-) and tau status (T+/-). 184 participants had undergone serial cerebrospinal fluid collection. Frequencies of risk factors and the Framingham Risk Score (FRS) were compared, and we tested the influence of risk factors on change in biomarker concentrations and cognition.Results: The absence of obesity, presence of hypertension, and a high FRS were associated with an increase in tau levels, particularly in A +T + individuals. Risk factors were not associated with amyloid. Depression was associated with higher cognitive scores, whereas high FRS was associated with lower scores and a faster decline.Discussion: Our results demonstrate that vascular risk factors may enhance neurodegeneration but not amyloid accumulation in preclinical AD. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Published
2019
Full Text
View/download PDF

30. O1‐09‐01: ESTIMATING YEARS FROM CLINICAL SYMPTOM ONSET FOR SPORADIC ALZHEIMER DISEASE: HOW FAR ARE WE?

Author

Randall J. Bateman, Anne M. Fagan, Chengjie Xiong, Suzanne E. Schindler, Marco Lorenzi, Scott M. Berry, Tammie L.S. Benzinger, John C. Morris, Yan Li, Guoqiao Wang, Andrew J. Aschenbrenner, Jason Hassenstab, Michael C. Donohue, and Eric McDade

Subjects
Pediatrics, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Neurology (clinical), Symptom onset, Geriatrics and Gerontology, Alzheimer's disease, business
Published
2019
Full Text
View/download PDF

31. O1‐01‐03: PLASMA Aβ42/Aβ40 PREDICTS HIPPOCAMPAL ATROPHY

Author

Randall J. Bateman, Yan Li, Anne M. Fagan, David M. Holtzman, Jorge J. Llibre Guerra, Suzanne E. Schindler, John C. Morris, James G. Bollinger, Vitaliy Ovod, Kwasi G. Mawuenyega, Tammie L.S. Benzinger, Brian A. Gordon, and Chengjie Xiong

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Hippocampal atrophy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Internal medicine, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2019
Full Text
View/download PDF

32. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease

Author

Randall J. Bateman, Neill R. Graff-Radford, Anne M. Fagan, Mathias Jucker, Chengjie Xiong, Carlos Cruchaga, Tammie L.S. Benzinger, John C. Morris, Suzanne E. Schindler, Jack H. Ladenson, Jasmeer P. Chhatwal, David M. Holtzman, Julia D. Gray, Kaitlin W. Todd, Rachel L. Henson, Leslie M. Shaw, John Q. Trojanowski, Danielle Graham, John M. Ringman, Yan Li, Johannes Levin, Jason Hassenstab, Guoqiao Wang, Elizabeth M. Herries, and James M. Noble

Subjects
0301 basic medicine, Male, Pathology, cerebrospinal fluid [Synaptosomal-Associated Protein 25], Epidemiology, genetics [Alzheimer Disease], Disease, cerebrospinal fluid [Amyloid beta-Peptides], 0302 clinical medicine, Cerebrospinal fluid, Medicine, Neurogranin, medicine.diagnostic_test, Health Policy, cerebrospinal fluid [Neurocalcin], Middle Aged, cerebrospinal fluid [Alzheimer Disease], Psychiatry and Mental health, cerebrospinal fluid [Biomarkers], Positron emission tomography, Disease Progression, Female, Alzheimer's disease, medicine.medical_specialty, Amyloid, Synaptosomal-Associated Protein 25, cerebrospinal fluid [Chitinase-3-Like Protein 1], genetics [Mutation], Article, 03 medical and health sciences, Cellular and Molecular Neuroscience, Developmental Neuroscience, Alzheimer Disease, Dementia, Humans, ddc:610, Chitinase-3-Like Protein 1, Neuroinflammation, Aged, Inflammation, Amyloid beta-Peptides, business.industry, medicine.disease, 030104 developmental biology, Neurocalcin, Positron-Emission Tomography, Mutation, Neurology (clinical), Geriatrics and Gerontology, cerebrospinal fluid [Neurogranin], business, 030217 neurology & neurosurgery, Biomarkers
Abstract

Introduction Four less well-studied but promising "emerging" cerebrospinal fluid (CSF) biomarkers are elevated in late-onset Alzheimer disease (AD): neurogranin, synaptosomal-associated protein-25 (SNAP-25), visinin-like protein 1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40). Methods CSF neurogranin, SNAP-25, VILIP-1, and YKL-40 were measured in families carrying autosomal-dominant AD mutations. Results The four emerging CSF biomarkers were significantly elevated in the mutation carriers (n = 235) versus noncarriers (n = 145). CSF SNAP-25, VILIP-1, and YKL-40 were altered very early in the AD time course, approximately 15–19 years before estimated symptom onset. All CSF biomarkers predicted important AD-related outcomes including performance on a cognitive composite, brain amyloid burden as measured by amyloid positron emission tomography, and the estimated years from symptom onset. Discussion Early abnormalities in CSF tTau, pTau, SNAP-25, VILIP-1, and YKL-40 suggest that synaptic damage, neuronal injury, and neuroinflammation begin shortly after the commencement of brain amyloid accumulation.

Published
2018
Full Text
View/download PDF

33. P4‐275: THE EMERGING CEREBROSPINAL FLUID BIOMARKER SNAP‐25 IS ELEVATED IN APOEε4 CARRIERS IN COGNITIVELY NORMAL INDIVIDUALS

Author

Brian A. Gordon, Anne M. Fagan, Tammie L.S. Benzinger, Courtney L. Sutphen, Chengjie Xiong, Jack H. Ladenson, Suzanne E. Schindler, Elizabeth M. Herries, and Carlos Cruchaga

Subjects
Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Snap, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Cerebrospinal fluid, Developmental Neuroscience, Medicine, Biomarker (medicine), Neurology (clinical), Geriatrics and Gerontology, business
Published
2018
Full Text
View/download PDF

34. P2‐295: QUANTIFYING THE CONTRIBUTIONS OF HERITABLE AND NON‐HERITABLE FACTORS TO AGE‐AT‐ONSET OF ALZHEIMER DEMENTIA IN ADULT CHILDREN OF AFFECTED PARENTS

Author

Carlos Cruchaga, John C. Morris, Greg S. Day, Suzanne E. Schindler, Dean W. Coble, and Thomas S. Wingo

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, Medicine, Neurology (clinical), Geriatrics and Gerontology, Alzheimer dementia, business, Clinical psychology
Published
2018
Full Text
View/download PDF

35. DT‐02‐01: APPROPRIATE USE CRITERIA FOR LUMBAR PUNCTURE AND CEREBROSPINAL FLUID TESTING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE

Author

Leslie M. Shaw, Jalayne J. Arias, Kaj Blennow, Doug R. Galasko, José Luis Molinuevo, Stephen Salloway, Suzanne E. Schindler, Maria C. Carrillo, James Hendrix, April Ross, Judit Illes, Courtney Ramus, and Sheila Fifer

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2018
Full Text
View/download PDF

36. IC-P-023: EARLY RESTING-STATE NETWORK DYSFUNCTION IN APOE ε4 CARRIERS WITHOUT BIOMARKER EVIDENCE OF ALZHEIMER'S DISEASE IS RELATED TO SUBCLINICAL TAU CHANGES

Author

Omar Butt, Anne M. Fagan, Carlos Cruchaga, John C. Morris, Tammie L.S. Benzinger, Beau M. Ances, Julie K. Wisch, and Suzanne E. Schindler

Subjects
Resting state fMRI, Epidemiology, business.industry, Health Policy, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Immunology, Medicine, Biomarker (medicine), Neurology (clinical), Geriatrics and Gerontology, business, Subclinical infection
Published
2019
Full Text
View/download PDF

37. [P3–205]: EMERGING CSF BIOMARKERS AS PREDICTORS OF ALZHEIMER DISEASE DEMENTIA

Author

Suzanne E. Schindler, Jack H. Ladenson, John C. Morris, Elizabeth M. Herries, and Anne M. Fagan

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, Csf biomarkers, medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, Alzheimer's disease, business
Published
2017
Full Text
View/download PDF

38. [O2–05–03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND IN VIVO AMYLOID IMAGING

Author

Richard Batrla-Utermann, Marian Quan, Anne M. Fagan, Virginia Buckles, Julia D. Gray, Suzanne E. Schindler, Tammie L.S. Benzinger, Chengjie Xiong, Brian A. Gordon, Simone Wahl, and John C. Morris

Subjects
Pathology, medicine.medical_specialty, Amyloid, Epidemiology, business.industry, Health Policy, Concordance, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, In vivo, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2017
Full Text
View/download PDF

39. IC-P-021: LONGITUDINAL CHANGES IN FUNCTIONAL CONNECTIVITY IN CONVERSION TO SYMPTOMATIC AD

Author

John C. Morris, Anne M. Fagan, Ganesh M. Babulal, Tammie L.S. Benzinger, Beau M. Ances, Catherine M. Roe, Suzanne E. Schindler, and Julie K. Wisch

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, Functional connectivity, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience
Published
2019
Full Text
View/download PDF

40. F2-07-01: BLOOD AMYLOID-BETA PREDICTS AMYLOID PET CONVERSION

Author

Dave M. Holtzman, Tammie L.S. Benzinger, Vitaliy Ovod, Kwasi G. Mawuenyega, John C. Morris, James G. Bollinger, Yan Li, Suzanne E. Schindler, Randall J. Bateman, Brian A. Gordon, Chengjie Xiong, and Anne M. Fagan

Subjects
Pathology, medicine.medical_specialty, biology, Epidemiology, Chemistry, Amyloid beta, Health Policy, Amyloid pet, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, biology.protein, Neurology (clinical), Geriatrics and Gerontology
Published
2019
Full Text
View/download PDF

41. P2-253: ANTEMORTEM CSF α-SYNUCLEIN PREDICTS TIME UNTIL DEATH IN AN AUTOPSY COHORT

Author

Suzanne E. Schindler, Hugo Vanderstichele, Anne M. Fagan, John C. Morris, Iswariya Venkataraman, Richard J. Perrin, Rachel L. Henson, and Fatima S. Amtashar

Subjects
Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Autopsy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Cohort, medicine, α synuclein, Neurology (clinical), Geriatrics and Gerontology, business
Published
2019
Full Text
View/download PDF

42. O2-02-04: CSF BIOMARKERS IN DOWN SYNDROME

Author

Benjamin L. Handen, Florence Lai, Eric Doran, H. Diana Rosas, Rachel L. Henson, Nicole Schupf, Brad T. Christian, Anne M. Fagan, Ira T. Lott, William E. Klunk, and Suzanne E. Schindler

Subjects
Down syndrome, Epidemiology, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Immunology, Csf biomarkers, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2019
Full Text
View/download PDF

43. O1‐05‐03: Upward Drift in CSf AB42 Values over 10 Years

Author

John C. Morris, Anne M. Fagan, Courtney L. Sutphen, and Suzanne E. Schindler

Subjects
0301 basic medicine, 03 medical and health sciences, Psychiatry and Mental health, Cellular and Molecular Neuroscience, 030104 developmental biology, 0302 clinical medicine, Developmental Neuroscience, Epidemiology, Chemistry, Health Policy, Neurology (clinical), Geriatrics and Gerontology, 030217 neurology & neurosurgery
Published
2016
Full Text
View/download PDF

44. P1‐006: Emerging CSF Biomarkers of Neuroinflammation, Neuronal Injury And Synaptic Integrity in the Adni Cohort

Author

Jack H. Ladenson, Anne M. Fagan, Elizabeth M. Herries, John C. Morris, Courtney L. Sutphen, Dan L. Crimmins, David M. Holtzman, and Suzanne E. Schindler

Subjects
020205 medical informatics, Epidemiology, business.industry, Health Policy, 02 engineering and technology, 03 medical and health sciences, Psychiatry and Mental health, Cellular and Molecular Neuroscience, 0302 clinical medicine, Developmental Neuroscience, Csf biomarkers, Cohort, 0202 electrical engineering, electronic engineering, information engineering, Medicine, 030212 general & internal medicine, Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience, Neuroinflammation
Published
2016
Full Text
View/download PDF

45. RACIAL DIFFERENCES AND SIMILARITIES IN MOLECULAR BIOMARKERS FOR AD

Author

Anne M. Fagan, Lena McCue, Tammie L.S. Benzinger, John C. Morris, Brian A. Gordon, Krista L. Moulder, Suzanne E. Schindler, Virginia Buckles, Elizabeth A. Grant, and Chengjie Xiong

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, business.industry, Evolutionary biology, Health Policy, Medicine, Racial differences, Neurology (clinical), Geriatrics and Gerontology, business, Molecular biomarkers
Published
2017
Full Text
View/download PDF

46. P4‐118: Neuropsychological determinants of stage 3 of preclinical Alzheimer disease

Author

Jason Hassenstab, Mateusz S. Jasielec, Chengjie Xiong, John C. Morris, Suzanne E. Schindler, and Anne M. Fagan

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Neuropsychology, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, Stage (cooking), Alzheimer's disease, business
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results